Rezolute, Inc. (RZLT): Entry into a Material Definitive Agreement
Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Transaction led by Frazier Life Sciences with participation from new and existing funds REDWOOD CITY, Calif., November 13, 2026 – Rezolute, Inc. (Na
- Instrument
- common stock and pre-funded warrants
- Gross proceeds
- approximately $100 million
- Shares
- 22,040,976 shares
- Price per share
- $3.87 per share
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The infusion of capital strengthens the balance sheet and funds upcoming commercialization efforts, but the issuance of new shares and warrants dilutes existing shareholders, likely prompting short‑term price pressure.
Market read
A material financing event for a small‑cap biotech, relevant for traders monitoring biotech capital raises and dilution risk.
What to watch
Potential strategic partnership with Frazier Life Sciences and the involvement of major banks may signal confidence in the pipeline.
Background
Rezolute is a Nasdaq‑listed biotech focused on refractory hypoglycemia caused by hyperinsulinism. The 8‑K filing announces the pricing of a $100 million equity and warrant offering led by Frazier Life Sciences.
Ticker impact
Rezolute disclosed pricing of a $100 million underwritten equity and pre‑funded warrant offering, the first public announcement of the raise.
likely modest downside as market prices in dilution, offset by support from new cash resources
A $100 M financing is material for a late‑stage biotech; investors typically react with slight price weakness due to dilution, though the cash runway can be viewed positively.
Market effects
Adds to recent financing activity in the ultra‑rare disease biotech sector, may set a pricing benchmark for similar companies.
Primarily affects US biotech investors; limited broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The raise could be a catalyst for upside if the cash accelerates product development and regulatory milestones.
Key entities
- companyRezolute, Inc.
Nasdaq‑listed biotech issuing new shares and warrants.
- financial_institutionFrazier Life Sciences
Lead underwriter of the offering.


